|
Scientific Agenda Conference Day – 1 |
||||
|
Time |
Hall A |
Hall B |
Hall C |
Hall D |
|
8.00 AM Onwards |
REGISTRATION |
REGISTRATION |
REGISTRATION |
REGISTRATION |
|
09.00 – 10.00 AM |
Oral Paper (Selected 6) |
Oral Paper (Selected 6) |
Oral Paper (Selected 6) |
Oral Paper (Selected 6) |
|
10.00 – 11.00 AM |
Scientific Program - Session 1 |
Scientific Program - Session 2 |
Scientific Program - Session 3 |
Scientific Program - Session 4 |
|
10.00 – 10.20 AM |
Thrombotic APLA : Diagnosis and management updates |
Thalassemia - refresher for primary care physicians |
Pediatric Early Warning Systems (PEWS) |
Stains in hematology |
|
10.20 – 10.40 AM |
Pregnancy in sickle cell anaemia |
Splenectomy in hemolytic anemia - when and how |
Special considerations during nursing care of the paediatric transplant patients |
Troubleshooting in coagulation lab |
|
10.40 – 11.00 AM |
HITT and VITT - Diagnosis and approach |
TDT and NTDT - Iron chelation and monitoring |
Methods of prevention of Infection in BMT/Neutropenia |
Quality assurance in hematology lab |
|
11.00 - 11:30 AM |
Tea break |
|||
|
11.30 – 1.00 PM |
Scientific Program - Session 5 |
Scientific Program - Session 6 |
Scientific Program - Session 7 |
Scientific Program - Session 8 |
|
11.30 – 11.50 AM |
Cancer associated thrombosis : |
Stem cell transplant - Basics |
Best practices and advancements in blood transfusion in BMT |
Setting up a molecular laboratory. |
|
11.50 AM – 12.10 PM |
Central venous access devices associated thrombosis |
Indications of stem cell transplant in current era |
Nutritional care in haematology patient: Role of the nurse |
Types of PCR and applications. |
|
12.10 – 12.30 PM |
Peri operative anti coagulation management |
Pre transplant work-up and LTFU program |
Care of the indwelling access device |
Cytogenetics studies in haematology:Tools |
|
12.30 – 12.50 PM |
Mannagement of thrombosis at unusual sites |
Complications of BMT |
Accreditation and Certification: Ensuring high standards in nursing practice and education |
Diagnosis of platelet function disorders - Nuances |
|
1.00 – 2.00 PM |
Lunch |
|||
|
2.00 – 3.00 PM |
Scientific Program - Session 9 |
Scientific Program - Session 10 |
Scientific Program - Session 11 |
Scientific Program - Session 12 |
|
2.00 – 2.20 PM |
Atypical infections in hematology |
Approach to the patient with excessive bleeding |
Chemotherapy basics and novel agents in hematology and BMT |
Work up of Hemoglobinopathies |
|
2.20 – 2.40 PM |
Assessment and management of invasive fungal pneumonia. |
Acquired haemophilia. |
Chemotherapy reconstitution and administration |
Sample collection, transport and storge |
|
2.40 – 3.00 PM |
Febrile neutropenia |
Bleeding with normal screening coagulogram |
Nursing care of chemotherapy extravasation. |
Oppurtunities for technologists in Hematology |
|
3.00 - 4.20 PM |
Scientific Program - Session 13 |
Scientific Program - Session 14 |
Scientific Program - Session 15 |
Scientific Program - Session 16 |
|
3.00-3.20 PM |
Approach to a patient of Neutropenia : |
Approach to the patient with DIC |
Laboratory monitoring of DOAC. |
Therapeutic apheresis - what we can do more? |
|
3.20 – 3.40 PM |
AIHA - management |
Reversal of DOACS/Superwarfarin/Heparins |
Lupus diagnosis: What clinician should know |
Apheresis for SDP and granulocytes |
|
3.40 – 4.00 PM |
Immune Thrombocytopenia |
Heavy Menstrual bleeding |
Thrombophilia testing when to test whom to test and what to test |
Stem cell sources, collection and preservation |
|
4.00 – 4.20 PM |
Macrophage activating syndrome |
Warfarin and Heparin resistance/IC bleed Hematological perspective - How to identify and manage |
Choosing Coagulation analyser- Smart way |
Stem cell/DLI manipulation |
|
4.20 – 4.40 PM |
Tea break |
|||
|
4.40 – 7.30 PM |
Session - 17 |
Scientific Program - Session 18 |
Scientific Program - Session 19 |
Scientific Program - Session 20 |
|
4.40 – 5.00 PM |
Inauguration |
Peripheral smear - Science or art |
Iron Metabolism - updates |
Pre and Post BMT transfusion - Transfusion medicine role |
|
5.00 – 5.20 PM |
Sickle emergencies |
Hemolytic anemia: Lab approach |
Iron replacement - How to do it right |
Massive transfusion protocol |
|
5.20 - 5.40 PM |
long-term complications of sickle |
Bone marrow : In whom, when, how, what |
Anemia of chronic diseases - Diagnosis and management |
Immune mediated hemolysis - Alloantibody identification |
|
5.40 – 6.20 PM |
Session 21 |
Scientific Program - Session 22 |
Scientific Program - Session 23 |
Scientific Program - Session 24 |
|
5.40 – 6.00 PM |
Thrombocytopenia |
Case bassed discussion on cell counter plots |
Approach to pancytopenia diagnosis: Causes of failed engine |
Pre operative work up for bleeding disorder |
|
6.00 – 6.20 PM |
Recurrent pregnancy loss – Hematological perspective |
How to choose cell counter when starting hematology lab |
Aplastic anemia - Basics |
Peri operative management in Sickle Cell disease |
|
6.20 – 7.30 PM |
Session - 25 Indian college of Haematology AOP – Paeds Bleeding child |
Scientific Program - Session 26 |
Scientific Program - Session 27 |
Scientific Program - Session 28 |
|
6.20 – 6.40 PM |
Thrombocytopenia |
Approach to Thrombocytosis |
How to identify MAHA |
Surgery in a patient on anticoagulants. |
|
6.40 – 7.00 PM |
Coagulopathy |
Approach to Eosinophilia |
Hematological emergencies in Obstetrics |
Anti coagulation in thrombocytopenic patients |
|
7.00 – 7.20 PM |
Pancytopenia |
Approach to Polycythemia |
HUS/TTP - Approach |
Anticoagulation in patients with organ dysfunction |
|
7.30 – 8.30 PM |
Chairperson: |
Chairperson: |
Chairperson: |
Chairperson: Dr Mundhra shailendra, Dr Rasika Gadkari |
|
7.30 – 8.00 PM |
Panel Discussion on Leucocytosis |
Panel discussion on AIHA |
Panel discussion on Eosinophillia |
Newer application of flowcytometry |
|
8.00 – 8.30 PM |
Panel Discussion on high Hemoglobin : |
Panel discussion on ITP |
Panel Discussion on Bleeeding in young female |
Choosing wisely - genetic testing tools in work up of hematological malignancy |
|
8.30 PM |
Dinner at : Centre point Hotel |
|||
|
Scientific Agenda Conference Day – 1 |
||||
|
Time |
Hall A |
Hall B |
Hall C |
Hall D |
|
8.00-9.00 AM |
REGISTRATION AND MEET THE PROFESSOR |
REGISTRATION AND MEET THE PROFESSOR |
REGISTRATION AND MEET THE PROFESSOR |
REGISTRATION AND MEET THE PROFESSOR |
|
9.00 - 10.00 AM |
Oral Paper (Selected 6) |
Oral Paper (Selected 6) |
Oral Paper (Selected 6) |
Oral Paper (Selected 6) |
|
10.00 – 11.00 AM |
Scientific Program - Session 29 |
Scientific Program - Session 30 |
Scientific Program - Session 31 |
Scientific Program - Session 32 |
|
10.00 – 10.20 AM |
HbF induction - update |
Hemophillia A - Prophylaxis in LMIC-Do's and Don' |
TKD mutation analysis - updates |
Allogeneic SCT - MSD, MUD, Haplo - LMIC challenges and solutions |
|
10.20 – 10.40 AM |
Pathophysiology and treatment of human hemolytic anemias Speaker: Dr.Mohandas Narla |
Optimising lab monitoring in hemophillia on newer products/ Role of chromogenic factor assay when to do and how to do |
Balancing the TKI equation - How much is enough ? Low dose vs TFR |
Infections in BMT Speaker: Dr.Sangeet Dadwal ( City Of Hope ) |
|
10.40 – 11.00 AM |
Transplants in Thalassemia - How to upscale to meet national demands : |
Gene Therapy for Hemophillia A |
Novel therapy /combinations in CML |
HLA and donor specific antibodies - Methods and implications |
|
11.00 - 11.15 AM |
Coffee Break |
|||
|
11.15 AM - 12.30 PM |
Session 33 - ISHBT-ASH Joint Symposium(Hall A) |
Session 33 - ISHBT-ASH Joint Symposium(Hall A) |
Session 33 - ISHBT-ASH Joint Symposium(Hall A) |
Session 33 - ISHBT-ASH Joint Symposium(Hall A) |
|
12.30 - 1.30 PM |
Industry Symposium 5 |
Industry Symposium 6 |
Industry Symposium 7 |
Industry Symposium 8 |
|
1.30 - 2.15 PM |
Lunch Break & Poster walk |
|||
|
2.15 – 3.15 PM |
Session 34-ISHBT-ASIAN Joint Symposium |
Session 35 - Dr. J G Parekh Oration |
Session 36 - panel discussion (30 min each ) |
Session 37 - Panel discussion (30 min) |
|
2.15 - 2.35 PM |
- |
- |
MPN cases |
Prevention of GVHD |
|
2.35 - 2.55 PM |
- |
- |
DIC |
Aplastic Anemia |
|
2.55 - 3.15 PM |
- |
- |
- |
- |
|
3.15 - 4.15 PM |
Session 38 - Session on Advances in Sickle Cell Disease Diagnosis and Therapy |
Session 39- AML |
Session 40 - Chronic Lymphocytic Leukemia |
Session 41 - Hemostasis, Laboratory and transfusion services |
|
3.15 - 3.35 PM |
Integrated point of care / advances for rapid and cost- effective screening / confirmation for Hb Pathies Speaker: Dr.Prof.Unmut Gurkan, Dr.PhD.Case Western, USA |
AML - Genomicandscape and genetic predisposition |
Treatment strategies in CLL : Evolving frontline treatment /Dual-targeted regimens for the frontline treatment of CLL |
Lab diagnosis and nuances - von Willebrand disease |
|
3.35 - 3.55 PM |
New and Emerging Pharmacological Therapies for SCD: Do we have magic bullets or should the search continue? Speaker: Dr.Zenaide Quezado, |
AML diagnosis WHO 2022: How to apply in Indian settings |
Nuances/toxicities of targeted therapies in CLL : How to manage? |
Platelet dysfunction work up and troubleshooting nuances |
|
3.55 - 4.15 PM |
Curative therapies (bone marrow transplant and gene therapy)for the treatment of sickle cell disease: Benefits and challenges Speaker: Dr.John Tisdale, M.D. |
AML - Personalised medicine from chemo to novel agents Speaker: Dr.Devendra Hiwase |
MRD directed therapy for CLL - Is it ready for prime time? |
Evolving trends in microangiopathic hemolytic anemia TTP / HUS Speaker: Dr.Ravi Sarode (USA) |
|
4.15-4.30 PM |
Tea break |
|||
|
4.30-5.30 PM |
Scientific Program - Session 42 |
Session 43 - AML 2 Chairperson: /p> |
Session 44 - Mature B cell Lymphoma Chairperson: /p> |
Session 45 - Primary immune deficiencies Chairperson: /p> |
|
4.30-4.50 PM |
Advancing the research priorities for India-specific comorbidities of SCD (It could be from scientific and/or policy perspective) |
AML - MRD monitoring - Is it ready for prime time? Speaker: |
Follicular Lymphoma - updates Speaker: |
Primary immune deficiency - Lab Approach made easy Speaker: |
|
4.50-5.10 PM |
New Information regarding SCD in India; Huge National Impact Speaker: |
TP53 mutated myeloid neoplasm Speaker: |
Mantle Cell Lymphoma - Novel strategies/combinations Speaker: |
PID - Infectious complications and management Speaker: |
|
5.10 PM - 5.30 PM |
National sickle cell disease mission of India: Promise, progress and beyond Speaker: |
Relapsed AML - Best way forward? Speaker: |
Marginal zone lymphoma - Approach Speaker: |
Special consideration in PID SCT Speaker: |
|
5.30 - 6.30 PM |
Scientific Program - Session 46 - Sickle Cell Disease Chairperson: - |
Session 47 - Myelodysplastic syndrome Chairperson: Dr. Afaq Ahmad Khan |
Session 48 - Aggressive lymphomas Chairperson: |
Session 49 - Rare hematological neoplasms Chairperson: |
|
5.30 - 5.50 PM |
Global Sickle Cell Disease Network (GSCDN): Goals for integration of a global approach for advancement of SCD treatment and care Speaker: Dr. Isaac Odame, |
Diagnosis of MDS- Recent updates Speaker: |
FCM approach to T CLPD- time to get away with TCR gene rearrangement Speaker: |
BPDCN: update Speaker: |
|
5.50 - 6.10 PM |
The journey towards India’s potential as a global leader for SCD Speaker: Dr.Kalpna Gupta, USA |
High risk MDS: Prognostication and Approach to management Speaker: Dr.Prof.Ghulam Mufti |
Double hit lymphoma - optimizing therapy Speaker: |
Novel therapeutic options for histiocytosis Speaker: |
|
6.10 - 6.30 PM |
Unconventional treatments Speaker: Dr.Sukanya Gogoi |
MDS - Transplant and supportive care considerations Speaker: |
Molecular profiling in DLBCL - Clinical implications Speaker: |
Advanced phase MPN clinical pearls Speaker: Dr.Aniket Bankar |
|
6.30 - 7.30 PM |
Industry Symposium 9 |
Industry Symposium 10 |
Industry Symposium 11 |
Industry Symposium 12 |
|
7.30 - 8.00 PM |
Inauguration Ceremony (Centre Point) |
|||
|
8.00 PM |
Dinner with cultural program - CP Hotel |
|||
|
Scientific Agenda Conference Day – 2 |
||||
|
Time |
Hall A |
Hall B |
Hall C |
Hall D |
|
7.00 AM |
Walk for Haematology |
|||
|
8.00-9.00 AM |
REGISTRATION AND MEET THE PROFESSOR |
|||
|
9.00 - 10.00 AM |
Oral Paper (Selected 6) |
Oral Paper (Selected 6) |
Oral Paper (Selected 6) |
Oral Paper (Selected 6) |
|
10.00 - 11.00 AM |
National Haematology Quiz among the Post Doctoral Student |
Session 50-ALL Chairperson: |
Session 51-Hodgkin Lymphoma Chairperson: |
Session 52-Aplastic anemia Chairperson: |
|
10.00-10.20 AM |
National Haematology Quiz among the Post Doctoral Student |
Genetic work up in a case of ALL- Practical testing approach in LMIC Speaker: |
Management of limited-stage Hodgkin lymphoma Speaker: |
How to optimise IBMF diagnosis in era of NGS -Which test to order Speaker: |
|
10.20-10.40 AM |
National Haematology Quiz among the Post Doctoral Student |
Treatment of ALL in LMIC - targeting the lacunae Speaker: /p> |
Hodgkin lymphoma treatment for older persons Speaker: /p> |
Optimizing management of aplastic anemia with ACE therapy Speaker: /p> |
|
10.40-11.00 AM |
National Haematology Quiz among the Post Doctoral Student |
Car T vs allogeneic SCT - in primary progressive ALL/Mechanism of escape in CAR T Cell therapy Speaker: |
The optimal management of relapsed and refractory Hodgkin lymphoma: post–brentuximab and checkpoint inhibitor failure Speaker: |
SCT - special considerations in IBMF Speaker: |
|
11.00 - 11.15 AM |
Coffee Break |
|||
|
11.15 AM - 12.30 PM |
Session 50-ISHBT-EHA Joint Symposium(Hall A) |
|||
|
12.30 - 1.30 PM |
Industry Symposium 13 |
Industry Symposium 14 |
Industry Symposium 15 |
- |
|
1.30 - 2.15 PM |
Lunch Break & Poster walk |
|||
|
2.15 - 3.15 PM |
Session 53 - Plasma Cell Disorders Chairperson: |
Session 54 - CART - 1 Chairperson: |
Session 55 - HLH Chairperson: |
Session 56 - Anemia 1 Chairperson: |
|
2.15 - 2.35 PM |
MGUS, Smoldering myeloma and myeloma management - where to draw the line Speaker: |
Bispecific CAR T cell Therapy in ALL Speaker: Prof Persis Amrolia |
Approach Speaker: |
Iron metabolism updates and approach to Iron deficiency Speaker: |
|
2.35 - 2.55 PM |
Approach to paraproteinemia and Updates in myeloma diagnosis = Mass FIX in LMIC Speaker: |
In house point of care management with in ALL CAR Speaker: Arnon Nagler |
Primary HLH and Nuances of BMT Speaker: |
Anemia of chronic inflammation/diseases - Novel therapies Speaker: |
|
2.55 - 3.15 PM |
LMIC and Myeloma Speaker: |
Developments in CAR T in India Speaker: |
Novel Therapies/Advances in HLH Speaker: |
How to approach a case of cryoglobulinemia Speaker: |
|
3.15 - 4.15 PM |
Session 57 - Plasma Cell Disorders 2 Chairperson: |
Session 58 - CART - 2 Chairperson: |
Session 59 - Complement and immune mediated diseases Chairperson: |
Session 60 - Anemia 2 Chairperson: |
|
3.15 - 3.35 PM |
MRD vs Peripheral blood myeloma monitoring Speaker: |
CAR T cell Therapy in MM Speaker: Dr.Arnon Nagler |
TTP/HUS Speaker: |
Anemia diagnosis- Solving riddle using newer hematopathology tools Speaker: |
|
3.35 - 3.55 PM |
Primary refractory and extra medullary disease - is there light at the end of the tunnel? Speaker: /p> |
In house local site CAR Manufacturing Speaker: Dr.Annalisa Ruggeri |
PNH Speaker: /p> |
Auto immune hemolytic anemia - Management Speaker: /p> |
|
3.55 - 4.15 PM |
MGCS - MGRS, MGNS, POEMS, TEMPI Speaker: |
CAR T cell Therapy in AML Speaker: Prof.Persis Amrolia |
Cold Agglutinin Disease Speaker: |
How to approach a case of cryoglobulinemia Speaker: |
|
4.15-4.30 PM |
Tea Break + Poster walk |
|||
|
4.30-5.30 PM |
Session 61 - Dr. Malti Sathe Chairpersons: - |
Session 62 - Recognizing, defining, and managing unusual hematologic toxicities Chairpersons: |
Session 63 - Thrombosis Chairpersons: |
Session 64 - Inpatient Hematology Emergencies Chairpersons: |
|
4.30-4.50 PM |
Session 61 - Dr. Malti Sathe Speaker: - |
CRS and management of CART Toxicities Speaker: Dr.Annalisa Ru geri |
The dos, don'ts, and nuances of thrombophilia testing Speaker: |
Role of critical care medicine in hematology Speaker: |
|
4.50-5.10 PM |
Session 61 - Dr. Malti Sathe Speaker: - |
Checkpoint inhibitors Speaker: p> |
How to diagnose and manage antiphospholipid syndrome Speaker: p> |
How to manage ITP with life-threatening bleeding Speaker: p> |
|
5.10-5.30 PM |
Session 61 - Dr. Malti Sathe Speaker: - |
Bispecific antibody therapies Speaker: /p> |
DOACs for acute DVT in patients with organ dysfunction Speaker: /p> |
Inpatient recognition and management of Hyperviscosity Speaker: /p> |
|
5.30 - 6.30 PM |
Session 65 - Plasma Cell Disorders 3 Chairperson: - |
Session 66 - Myelofibrosis Chairperson: |
Session 67- Bleeding Chairperson: |
Session 68- Things not talked about Chairperson: |
|
5.30 - 5.50 |
AL amyloidosis: Updates in diagnosis and management Speaker: |
Approach to diagnosis Speaker: |
How to assess and manage hemostasis in patients with severe liver disease during intervention/Liver transplantation Speaker: |
How to setup Hematology/BMT unit in public health center Speaker: |
|
5.50- 6.10 |
Waldenstrom's Macroglobulinemia Speaker: /p> |
Transplant in Myelofibrosis - Art of balance Speaker: /p> |
How to manage bleeding on novel agents for Hemophilia Speaker: /p> |
AI in Hematologist's life Speaker: /p> |
|
6.10-6.30 |
When a hematologist becomes a Myeloma patient Speaker: |
Evolving landscape of JAK inhibition/Novel Therapies in MF Speaker: |
When to suspect, how to diagnose and manage acquired VWD Speaker: |
How to strike a balance between clinical responsibilities and research in India Speaker: |
|
6.00 - 7.00 PM |
Industry Symposium 17 |
Industry Symposium 18 |
Industry Symposium 19 |
Industry Symposium 20 |
|
7.00 - 8.00 PM |
Annual GBM Hall - A |
|||
|
8.00 PM |
Gala Dinner at : River Front |
|||
|
Scientific Agenda Conference Day – 3 |
||||
|
Time |
Hall A |
Hall B |
Hall C |
Hall D |
|
7.00-8.00 AM |
Meet the professor |
|||
|
8.00-9.00 AM |
NATIONAL HEMATOLOGY ISHBT QUIZ FINAL |
|||
|
9.00am to 10.00am |
Oral Paper (Selected 6) |
Oral Paper (Selected 6) |
Oral Paper (Selected 6) |
Oral Paper (Selected 6) |
|
10.00-10.15 AM |
Tea Break |
|||
|
10.15-11.45 AM |
Session 69 - Dr.J C Patel Award Session (Hall A) |
|||
|
11.45-12.45 PM |
Session 70 - Interesting case Based Learning (Laboratory-15 mins Each) |
Session 71 - Interesting case Based Learning (Clinical-15 mins Each) |
Session 72 - Consultative Haematology-1 |
Session 73 - Consultative Haematology-2 |
|
11.45-12.00 PM |
Haemolytic anaemia Speaker: |
Inherited bone marrow failure. Speaker: |
Unusual site thrombosis - Approach Speaker: |
Isolated PT/APTT prolongation - Approach Speaker: |
|
12.00-12.15 PM |
AML Speaker: |
HSCT complication Speaker: |
Splenomegaly - Approach Speaker: |
Von willebrand - Peri partum management Speaker: |
|
12.15-12.30 PM |
MDS Speaker: |
Immune thrombocytopenia Speaker: |
Thrombocytosis/Polycythemia - Approach Speaker: |
Heavy Menstrual bleeding - Approach Speaker: |
|
12.30-12.45 PM |
CLPD Speaker: |
Acute Myeloid Leukemia Speaker: |
Deep vein thombosis - Approach Speaker: |
Peri operative management of anticoagulation - Approach Speaker: |
|
12.45-1.45 PM |
Session 74 - Bench to bed side : Chairpersons: |
Session 75 - Debate Chairpersons: |
Session 76 - Consultative Haematology-3 Chairpersons: |
Session 77- Consultative Haematology-4 Chairpersons: |
|
12.45-1.05 PM |
NGS work up of hemolytic anemia Speaker: |
Debate 1 - (15 mins +15 mins +5 mins) Speaker: |
Management of DIC Speaker: |
Abnormal blood counts in pregnancy? Speaker: |
|
1.05 - 1.25 PM |
Cytotoxic T cell for refractory viral infection Speaker: |
Debate 2 - 15mins +15 mins +5 mins: Immunotherapy in hodgkin disease replaces SCT Speaker: |
Management of intracranial bleed in ITP Speaker: |
Anticoagulation in pregnancy Speaker: |
|
1.25 - 1.45 PM |
Optical genome mapping - clinical relevance Speaker: |
- - - |
Leukocytosis - Approach Speaker: |
Anemia in pregnancy Speaker: |
|
1.45 PM Onwards |
VALEDICTORY FUNCTION AND PRIZE DISTRIBUTION FOLLOWED BY LUNCH |
|||